SCHEMBL6236397

SCHEMBL6236397

Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OCC(=O)O

nearest known ligand 0.78

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 0.78
PPARA Q07869 10/20 0.78
PPARG P37231 4/20 0.78
MEN1 O00255 1/20 0.71
ALDH1A1 P00352 1/20 0.71
CYP3A4 P08684 1/20 0.71
MAPT P10636 1/20 0.71
HPGD P15428 1/20 0.71
ALOX15 P16050 1/20 0.71
KMT2A Q03164 1/20 0.71
HSD17B10 Q99714 1/20 0.71
FFAR1 O14842 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw501516 SCHEMBL68714 0.88 PPARD (1.00) PPARDPPARAPPARGMEN1ALDH1A1
Gw501516 SCHEMBL29356729 0.88 PPARD (1.00) PPARDPPARAPPARGMEN1ALDH1A1
Sodelglitazar SCHEMBL29378834 0.87 PPARD (0.59) PPARDPPARAPPARGMEN1ALDH1A1
Sodelglitazar SCHEMBL4822839 0.87 PPARD (0.59) PPARDPPARAPPARGMEN1ALDH1A1
Sodelglitazar SCHEMBL29801577 0.87 PPARD (0.59) PPARDPPARAPPARGMEN1ALDH1A1
SCHEMBL5519969 0.87 PPARD (0.98) PPARDPPARAPPARGMEN1ALDH1A1
SCHEMBL6236375 0.86 PPARD (0.86) PPARDPPARAPPARGMEN1ALDH1A1
SCHEMBL6302340 0.85 PPARD (0.74) PPARDPPARAPPARGMEN1ALDH1A1
SCHEMBL6385692 0.84 PPARD (0.53) PPARDPPARAPPARGMEN1ALDH1A1
SCHEMBL5517514 0.83 PPARD (0.88) PPARDPPARAPPARGMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189895-B8 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORP (US) 2005-11-09 EP disclosed
EP-1189895-B1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM CORP (US) 2005-06-08 EP disclosed
US-6723740-B2 ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES SMITHKLINE BEECHAM CORPORATION 2004-04-20 US disclosed
US-6710063-B1 Activators of PPAR delta SMITHKLINE BEECHAM CORPORATION 2004-03-23 US disclosed
US-20030203947-A1 Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides CHAO ESTHER YU-HSUAN (US) 2003-10-30 US disclosed
EP-1189895-A1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE GLAXO GROUP LIMITED (GB) 2002-03-27 EP disclosed
WO-2001000603-A1 THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE GLAXO GROUP LIMITED (GB) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203947-A1 Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides PPARA, PPARD, PPARG PPARD 2/4885PPARA 1/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.